Soleus Capital Management, L.P. Biogen Inc. Transaction History

Soleus Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $15.4 Million - $19.5 Million	72,800 New	72,800 $15.7 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $4.52 Million - $6.23 Million	23,200 New	23,200 $6.19 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $947,262 - $1.11 Million	-3,899 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $1.81 Million - $2.72 Million	-7,657 Reduced 66.26%	3,899 $955,000
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $2.45 Million - $2.83 Million	9,256 Added 402.43%	11,556 $3.28 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $181,062 - $239,785	-700 Reduced 23.33%	2,300 $615,000
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $1.21 Million - $1.53 Million	-4,500 Reduced 60.0%	3,000 $949,000
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $1.65 Million - $2.28 Million	7,500 New	7,500 $2.23 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.